TSG101 peptide (ab30870)
Key features and details
- Purity: > 90% HPLC
- Suitable for: Blocking
製品の詳細
-
製品名
TSG101 peptide -
精製度
> 90 % HPLC. -
アクセッション番号
-
Animal free
No -
由来
Synthetic -
関連製品
-
Corresponding Antibody
特性
Our Abpromise guarantee covers the use of ab30870 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
-
アプリケーション
Blocking - Blocking peptide for Anti-TSG101 antibody (ab30871)
-
製品の状態
Liquid -
備考
- First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
- If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
- Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
- Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
- Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use. -
Concentration information loading...
前処理および保存
-
保存方法および安定性
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Information available upon request.
関連情報
-
別名
- ESCRT I complex subunit TSG101
- ESCRT-I complex subunit TSG101
- TS101_HUMAN
see all -
機能
Component of the ESCRT-I complex, a regulator of vesicular trafficking process. Binds to ubiquitinated cargo proteins and is required for the sorting of endocytic ubiquitinated cargos into multivesicular bodies (MVBs). Mediates the association between the ESCRT-0 and ESCRT-I complex. Required for completion of cytokinesis; the function requires CEP55. May be involved in cell growth and differentiation. Acts as a negative growth regulator. Involved in the budding of many viruses through an interaction with viral proteins that contain a late-budding motif P-[ST]-A-P. This interaction is essential for viral particle budding of numerous retroviruses. -
組織特異性
Heart, brain, placenta, lung, liver, skeletal, kidney and pancreas. -
配列類似性
Belongs to the ubiquitin-conjugating enzyme family. UEV subfamily.
Contains 1 SB (steadiness box) domain.
Contains 1 UEV (ubiquitin E2 variant) domain. -
ドメイン
The UEV domain is required for the interaction of the complex with ubiquitin. It also mediates the interaction with PTAP/PSAP motifs of HIV-1 P6 protein and human spumaretrovirus Gag protein.
The coiled coil domain may interact with stathmin.
The UEV domain binds ubiquitin and P-[ST]-A-P peptide motif independently. -
翻訳後修飾
Monoubiquitinated at multiple sites by LRSAM1 and by MGRN1. Ubiquitination inactivates it, possibly by regulating its shuttling between an active membrane-bound protein and an inactive soluble form. Ubiquitination by MGRN1 requires the presence of UBE2D1. -
細胞内局在
Cytoplasm. Membrane. Nucleus. Late endosome membrane. Mainly cytoplasmic. Membrane-associated when active and soluble when inactive. Depending on the stage of the cell cycle, detected in the nucleus. Colocalized with CEP55 in the midbody during cytokinesis. - Information by UniProt
画像
-
TSG101 peptide (ab30870)
プロトコール
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (2)
ab30870 は 2 報の論文で使用されています。
- Chang CJ et al. Distinct Proteomic Profiling of Plasma Extracellular Vesicles from Moderate-to-Severe Atopic Dermatitis Patients. Clin Cosmet Investig Dermatol 14:1033-1043 (2021). PubMed: 34471367
- Dookun E et al. Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery. Aging Cell 19:e13249 (2020). PubMed: 32996233